Navigation Links
US WorldMeds Announces the Launch of Revonto™ (dantrolene sodium for injection)

LOUISVILLE, Ky., July 6 /PRNewswire/ -- US WorldMeds is proud to announce the launch of Revonto™ (dantrolene sodium for injection), the first patented scientific advancement in the treatment of malignant hyperthermia (MH).  The time to reconstitute dantrolene sodium for injection has been dramatically reduced to approximately 20 seconds or until the solution is clear.  Revonto™ retains the cost-savings of the original dantrolene sodium for injection product while offering a significant improvement in pharmacotherapy.

"The enhanced reconstitution time is an important and critical scientific improvement to intravenous dantrolene sodium, the only available antidote for the treatment of malignant hyperthermia.  MH is triggered in some patients by certain inhalation anesthetics during surgery.  A rapid response to MH onset is critical because temperatures exceeding 105F degrees and death due to this condition can occur as early as 30 minutes from onset." says Dr. George A. Digenis, Chief Scientific Officer of US WorldMeds.

Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy.  There have been reports of thrombophlebitis following administration of intravenous dantrolene.  There have been rare reports of urticaria and erythema possibly associated with the administration of i.v. dantrolene sodium. For additional information, including the full prescribing information for Revonto™, please visit US WorldMeds' website at

For more information on malignant hyperthermia, please visit The Malignant Hyperthermia Association of the United States (MHAUS) website at

Revonto™ will be available on GPO contracts as a dropship via your wholesaler/distributor.

For Ordering Information Call: 1.877.411.USWM(8796).

About US WorldMeds

US WorldMeds, LLC, a specialty pharmaceutical company located in Louisville, Kentucky, is committed to developing, licensing, and marketing unique and significant pharmaceuticals that address unmet medical needs. US WorldMeds is committed to using science to make lives better. For more information, please visit

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces a $15 Million At-The-Market Firm Commitment Financing Agreement
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Second Quarter 2010 Results
3. Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin®
4. Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
5. PolyTouch Medical Ltd. Announces the Appointment of Robert D. Fanelli, MD, FACS, FASGE as Medical Advisor
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
7. ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
8. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
9. Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO
10. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
11. Sysmex America Announces Executive Leadership Changes
Post Your Comments:
(Date:12/1/2015)... och UPPSALA, Sverige, December 1, 2015 ... International Breast Cancer Study Group (IBCSG, ... Bryssel) att ingå i en klinisk studie av ... --> --> Studien, med namn ... behandlas med anti-hormonella läkemedel i kombination med palbociclib, ...
(Date:11/30/2015)... Minn. and BASEL, Switzerland ... Laboratories, Inc. (Upsher-Smith), through its wholly-owned UK subsidiary ... further development of a novel, oral small molecule inhibitor ... that may be effective in the treatment of inflammatory ... clinical development. --> --> ...
(Date:11/30/2015)... 1, 2015 Express Scripts (NASDAQ: ESRX ) ... IMMY ) to drive access to a low-cost alternative to ... toxoplasmosis that has been recently priced out of reach for ... systems. --> --> Imprimis ... (a form of folic acid) for $1 per capsule for people ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, ... in the United States. Clarity is a Superior Dual Wavelength Platform which combines ... single platform that is easy to own and operate. , For over a ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, ... addresses a main “pain point” for merging or aligning healthcare provider organizations—when mergers ... is signed. This quick-read guidance suggests that failing to recognize the power ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - CES, Las Vegas, ... Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, where they will ... Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a ... and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves ... a significant amount of time in Sweden since joining PartnerTech based in Malmo, ...
Breaking Medicine News(10 mins):